Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Iproceedings

Date Submitted: Jan 16, 2022
Date Accepted: Jan 24, 2022

The final, peer-reviewed published version of this preprint can be found here:

Pattern of Comorbidities and the Impact on Outcomes in Patients With COVID-19 in Babel Governorate, Iraq, in 2020

Hussein A, Lami F

Pattern of Comorbidities and the Impact on Outcomes in Patients With COVID-19 in Babel Governorate, Iraq, in 2020

Iproc 2022;8(1):e36511

DOI: 10.2196/36511

The Pattern of Comorbidities among COVID-19 Patients and their Impact on the Outcome in Babel Governorate/ Iraq-2020

  • Alaa Hussein; 
  • Faris Lami

ABSTRACT

Background:

Background:

The presence of comorbidity poses a major clinical challenge in the care and treatment of COVID-19 patients.

Objective:

Objective:

To evaluate the effects of common comorbidities on the severity, outcome, and length of stay in the hospital of COVID-19 patients, Babel Governorate, Iraq, 2020.

Methods:

Methods All the laboratory-confirmed cases in the two COVID-19 hospitals in Babel governorates during March through September 2020 were included. A form was developed to compile socio-demographic data, clinical presentation, and severity, comorbidities, length of

Results:

Results The total number of patients was 2574; 1581 (61.4%) were males. The mean age was 48.7 (±16.4) years. The severe cases were 1212 (47.1%), and critical were 489 (19.0%). The patients with no comorbidity were 1543 (59.9%); 536 (20.9%) had one comorbidity were, and 495 (19.2%) had two or more comorbidities. The most prevalent comorbidity was Diabetes Mellitus (25.0%), followed by hypertension (23.4%). The proportion of the severe/critical cases was 84.0% among the patients with comorbidity compared to 54.1% among the patients free from comorbid illnesses (P<0.001). Around 12% of patients with comorbidity had a mean hospitalization time >2 weeks compared to 8.0% among the patients with no comorbidity (P<0.001). The case-fatality ratio was 26.4% among patients with comorbidities compared to 10.6% among the patients free from comorbidity (P<0.001).

Conclusions:

Conclusions:

Comorbid illnesses are a significant predictor of serious hospital course and fatal outcome of COVID-19 patients. Those patients must undertake vigilant preventive measures and should have the priority to get the COVID-19 vaccine.


 Citation

Please cite as:

Hussein A, Lami F

Pattern of Comorbidities and the Impact on Outcomes in Patients With COVID-19 in Babel Governorate, Iraq, in 2020

Iproc 2022;8(1):e36511

DOI: 10.2196/36511

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.